INTRODUCTION

Over the last four decades, China has experienced rapid demographic and epidemiological transitions. Rapid industrialization, urbanization, aging, and changes in lifestyle have led to a shift in the burden of the disease spectrum from infectious diseases to non-communicable diseases. \(^1\) China has been an important contributor to the global cancer burden because of its large population.

Gastric cancer is a common cancer worldwide. One in 78 women and one in 33 men develop gastric cancer over their lifetime. \(^2\) According to GBD 2019, the DALYs in China...
accounted for 44.21% of the total number.\(^3\) Gastric cancer is the second most frequently diagnosed cancer and the second leading cause of cancer-related deaths in China.\(^4\) The disease burden of gastric cancer in China is high. Comparison of the gastric cancer metrics and trends in China and other countries is of great value for developing various health policies. Moreover, reports on the spatial distribution and trends in gastric cancer would help policy makers allocate resources properly.

In this study, we extracted age-standardized rates (ASRs) for gastric cancer from the Global Burden of Disease (GBD) study. The trends of ASRs could be a surrogate for the changing disease patterns and reflect the shift in risk factors. The estimated annual percentage changes (eAPCs) are broadly used to measure time trends in ASRs. To provide an updated picture of epidemiological trends and geographic patterns of gastric cancer, we considered temporal variations in incidence, mortality rates, disability-adjusted life-years (DALYs), and APCs according to age, sex, and region in China and the world.

2 | METHODS

2.1 | Data sources

2.1.1 | The Global Burden of Disease Project

The Global Burden of Disease (GBD) project presents the cancer incidence, mortality, years of life lost (YLLs), years lived with disability (YLDs), and disability-adjusted life-years (DALYs).\(^3\) The GBD project collected and analyzed the data for more than 350 diseases and injuries in 195 countries. The Global Health Data Exchange (GHDx) online data source query tool\(^5\) provides comparisons by age, sex, age groups, and geography from 1990 till date. This project helps visualize health trends over time as well as develop cancer control strategies to achieve global targets and improve equity in cancer care.

We collected the incidence, mortality, and DALYs of gastric cancer, and measured ASRs from 1990 to 2019 according to sex, five socio-demographic indices (SDI), 21 regions, and 195 countries/territories. The five SDI categories (low, low-middle, middle, high-middle, and high SDI) are also described by the GBD project 2017.\(^6\) The ASRs per 100,000 person-years are calculated using WHO world standard population.\(^7\)

2.2 | Statistical analyses

We gleaned data from the GBD database to examine the epidemiology trends in gastric cancer from 1990 to 2019. Only the age-specific rates in 2019 were incorporated into the study. The ASRs from GBD were calculated using the WHO world standard population.

The estimated APCs were calculated as follows:

\[
\ln(ASR) = a + bx + e, \quad \text{EstimatedAPCs} = 100 \times (\exp(b) - 1),
\]

Where \(x\) refers to the calendar year.

The R program (R 3.5.1) was used for statistical analyses and preparing the plots.

3 | RESULTS

3.1 | Incidence of gastric cancer

The incident cases in China presented a similar trend, increasing from 317,340 cases (95% UI = 277,900–359,320 cases) in 1990 to 612,820 cases (95% UI = 513,000–728,890 cases) in 2019 (Table 1). In 2019, Mainland China had a higher ASIR (30.64/100,000, 95% CI = 25.82–36.15/100,000) than the world average (15.59/100,000, 95% CI = 14.11–17.15/100,000) (Figure 1A; Table 2). ASIR decreased in Mainland China (eAPC = −0.18, 95% CI = −0.33 to 0.01) from 1990 to 2019. The ASIR for males remained stable (eAPC = −0.07, 95% CI = −0.29 to 0.23) during the study period, meanwhile the indicator experienced a downward tendency for females (eAPC = −0.38, 95% CI = −0.53 to −0.20) (Table 2; Table S1; Figure 2A).

The global incident cases of gastric cancer went upward from 883,400 cases (95% UI = 834,240 to 929,170 cases) in 1990 to 1,269,810 cases (95% UI = 1,150,490 to 1,399,820 cases) in 2019, corresponding to an increase of 43.74% (Table 1). The incident cases in all SDI quintiles went upward. The low-middle SDI quintile had the highest increase of 73.15%, whereas the high-SDI quintile had the lowest increase of 4.48% (Table 1).

According to GBD 2019,\(^3\) in 204 countries and territories, Mongolia displayed the highest ASIR of 43.7/100,000 (95% CI = 34.29–55.1/100,000), and was followed by Bolivia (34.02/100,000, 95% CI = 26.85–42.02/100,000), China (30.64/100,000, 95% CI = 25.82–36.15/100,000), South Korea (28.67/100,000, 95% CI = 23.65–34.17/100,000), and Japan (28.29/100,000, 95% CI = 23.71–33.27/100,000). The lowest ASIR was observed in Malawi (3.28/100,000, 95% CI = 2.67–3.91/100,000) (Figure 1A; Table S1; Figure 2A).

In terms of geographic regions, the ASIR was the highest in East Asia (30.24/100,000, 95% CI = 25.55–35.54/100,000) and the lowest in High-income North America (6.12/100,000, 95% CI = 5.38–6.95/100,000) in 2019. The ASIR for males

\[
\ln(ASR) = a + bx + e, \quad \text{EstimatedAPCs} = 100 \times (\exp(b) - 1),
\]

Where \(x\) refers to the calendar year.

The R program (R 3.5.1) was used for statistical analyses and preparing the plots.
TABLE 1 The incidence, death, DALY, and their change trends of stomach cancer from 1990 to 2019

| Characteristics | Incident cases (NO.) | Deaths (NO.) | DALYS (NO.) |
|-----------------|----------------------|--------------|-------------|
|                 | 1990                  | 2019         | 1990–2019   | 1990–2019 increase (%) | 1990                  | 2019         | 1990–2019       | 1990–2019 increase (%) |
|                 | Both (95% UI)         | Male/ Female ratio | Both (95% UI) | Male/ Female ratio | Both (95% UI) | Male/ Female ratio | Both (95% UI) | Male/ Female ratio |
| Global          | 834.40 (834.24,929.17) | 1.63          | 1269.81 (1150.49,1399.82) | 2.00          | 43.74%          | 788.32 (742.79,834.00) | 1.57          | 21.42%          |
| China           | 317.54 (277.90,359.32) | 1.89          | 612.82 (513.00,728.89) | 2.79          | 93.11%          | 305.47 (267.21,345.40) | 1.82          | 38.00%          |
| SDI             |                       |               |               |               |               |               |               |               |
| Low SDI         | 26.77 (23.56,29.94)   | 1.49          | 41.31 (37.01,45.96) | 1.21          | 54.33%          | 27.14 (24.01,29.95) | 1.52          | 61.64%          |
| Low-middle SDI  | 85.80 (78.53,93.23)   | 1.38          | 148.56 (135.58,162.71) | 1.35          | 73.15%          | 85.48 (78.26,91.91) | 1.38          | 66.07%          |
| Middle SDI      | 251.42 (226.67,277.98) | 1.71         | 396.75 (349.28,452.22) | 1.85          | 57.81%          | 244.35 (221.14,268.69) | 1.66          | 41.30%          |
| High-middle SDI | 291.59 (275.03,308.00) | 1.67        | 380.86 (337.20,427.02) | 2.27          | 30.61%          | 276.44 (250.10,307.70) | 2.01          | 163%            |
| High SDI        | 227.56 (219.66,231.99) | 1.64        | 237.76 (209.74,260.86) | 1.78          | 4.48%           | 154.66 (148.23,157.91) | 1.49          | 6.38%           |
| Region          |                       |               |               |               |               |               |               |               |
| Andean Latin America | 5.98 (5.44,6.54)  | 1.25          | 12.37 (10.07,15.03) | 1.26          | 107.06%         | 6.20 (5.65,7.69) | 1.23          | 90.10%         |
| Australasia     | 2.38 (2.28,2.48)      | 1.69          | 3.45 (2.79,4.21) | 1.74          | 44.78%          | 1.76 (1.68,1.82) | 1.56          | 16.16%          |
| Caribbean       | 2.92 (2.67,3.10)      | 1.61          | 4.36 (3.76,4.97) | 1.52          | 48.95%          | 2.93 (2.67,3.13) | 1.58          | 40.38%          |
| Central Asia    | 13.39 (12.98,13.76)   | 1.64          | 12.13 (10.99,13.40) | 1.74          | -9.45%          | 13.18 (12.77,13.54) | 1.59          | -11.70%         |
| Central Europe  | 26.46 (25.82,26.92)   | 1.71          | 21.72 (19.11,24.41) | 1.78          | -17.92%         | 26.33 (25.63,26.81) | 1.66          | -23.61%         |
| Central Latin America | 15.50 (14.96,15.89) | 1.22        | 30.51 (25.95,35.82) | 1.19          | 96.88%          | 15.45 (14.84,18.84) | 1.23          | 76.74%          |
| Central Sub-Saharan Africa | 2.72 (2.21,3.29) | 1.72        | 4.25 (3.38,5.31) | 1.60          | 55.97%          | 2.75 (2.30,3.26) | 1.77          | 55.42%          |
| East Asia       | 325.71 (285.49,367.29) | 1.89       | 626.49 (526.59,741.27) | 2.77          | 92.34%          | 313.10 (274.77,353.49) | 1.81          | 38.29%          |

(Continues)
| Region                  | Incident cases (NO.) | Deaths (NO.) | DALYs (NO.) | Both Male/Female ratio | Male (95% UI) (No. × 1000) | Female (95% UI) (No. × 1000) | DALYs (95% UI) (No. × 1000) |
|-------------------------|----------------------|--------------|-------------|------------------------|-----------------------------|----------------------------|-----------------------------|
| Eastern Europe (87.03)  | 1.35                 | 1.44         | −17.02%     | 0.59, 0.62             | 128.63 (41.84, 11.13)       | 128.63 (41.84, 11.13)       | 128.63 (41.84, 11.13)       |
| Eastern Sub-Saharan Africa (8.23) | 1.46 | 1.17 | 8.34 | 3.87, 3.34 | 128.63 (41.84, 11.13) | 128.63 (41.84, 11.13) | 128.63 (41.84, 11.13) |
| Middle East (26.39)     | 1.72                 | 1.69         | 9.04%       | 99.55, 99.55           | 128.63 (41.84, 11.13)       | 128.63 (41.84, 11.13)       | 128.63 (41.84, 11.13)       |
| North Africa (20.93)    | 1.49                 | 1.49         | 23.93%      | 23.93, 23.93           | 128.63 (41.84, 11.13)       | 128.63 (41.84, 11.13)       | 128.63 (41.84, 11.13)       |
| South Asia (57.87)      | 1.65                 | 1.64         | 12.75%      | 12.75, 12.75           | 128.63 (41.84, 11.13)       | 128.63 (41.84, 11.13)       | 128.63 (41.84, 11.13)       |
| Southeast Asia (28.07)  | 1.65                 | 1.64         | 12.75%      | 12.75, 12.75           | 128.63 (41.84, 11.13)       | 128.63 (41.84, 11.13)       | 128.63 (41.84, 11.13)       |
| Tropical Latin America (8.46) | 1.49 | 1.49 | 8.34 | 3.87, 3.34 | 128.63 (41.84, 11.13) | 128.63 (41.84, 11.13) | 128.63 (41.84, 11.13) |
| Western Europe (93.95)  | 1.35                 | 1.44         | −17.02%     | 0.59, 0.62             | 128.63 (41.84, 11.13)       | 128.63 (41.84, 11.13)       | 128.63 (41.84, 11.13)       |

**Abbreviations:** DALY, disability-adjusted life year; SDI, socio-demographic index; UI, uncertain interval.
was 1.10–3.0 times higher than that for females (Table 2). Overall, the global ASIR showed a decreasing trend from 1990 to 2019 (Figure 2B), with the largest decline in High-income Asia Pacific (eAPC = −0.54, 95% CI = −0.60 to −0.48). The ASIR performed a downward tendency in all SDI quintiles, whereas the high SDI countries exhibited the most significant decline (eAPC = −0.44, 95% CI = −0.48 to −0.38) (Table 2).

### 3.2 Mortality of gastric cancer

Gastric cancer caused 421,540 deaths (95% UI = 353,520 to 493,180) in China in 2019, corresponding to a 38% increase from the 305,470 deaths (95% UI = 267,210 to 345,400 deaths) in 1990 (Table 1). The ASMR in China showed an overall downward trend during the period (eAPC = −0.42, 95% CI = −0.47 to −0.36) (Figure 2C). The ASMR among females conducted a more conspicuous declining tendency (eAPC = −0.53, 95% CI = −0.63 to −0.40) than that of males (eAPC = −0.35, 95% CI = −0.50 to −0.16) (Table 2; Table S1).

From 1990 to 2019, the global gastric cancer deaths increased by 21.42%, from 788,320 deaths (95% UI = 742.79 to 834,000) to 957,190 deaths (95% UI = 870,950 to 1,034,650). Geographically, Oceania presented the largest increase in deaths (121.60%) while Eastern Europe took the least (−44.39%) (Table 1). Besides, the death cases showed an increasing trend among all SDI quintiles. The middle-SDI quintile presented the highest deaths of gastric cancer (345,270 deaths, 95% CI = 305,030 to 387,650 deaths), whereas the low-SDI quintile had the lowest (438,800 deaths, 95% UI = 393,100 to 489,000 deaths) in 2019 (Table 1).

Figure 1B shows the ASMR in different countries and territories. The ASMR ranked highest in Mongolia (40.04/100,000, 95% CI = 36.3–57.48/100,000), followed by Bolivia (36.11/100,000, 95% CI = 28.77–44.26/100,000), Afghanistan (29.3/100,000, 95% CI = 21.25–36.25/100,000), and Guatemala (27.97/100,000, 95% CI = 22.45–34.43/100,000), whereas the ASMR was lowest in the United States of America (3.4/100,000, 95% CI = 3.19–3.54/100,000). In addition, the highest decrease was demonstrated in Republic of Korea (eAPC= −0.73, 95% CI = −0.76 to −0.70) (Table S2).

In terms of geographic regions, the ASMR was highest in Andean Latin America (21.51/100,000, 95% CI = 17.55–25.91/100,000) and East Asia (21.51/100,000, 95% CI = 18.23–24.95/100,000). Oppositely, the lowest ASMR was displayed in High-income North America (3.51/100,000, 95% CI = 3.29–3.66/100,000) in 2019 (Table 2). Overall, the ASMR decreased in all regions from 1990 to 2019, with the most remarkable drop in High-income Asia Pacific (eAPC= −0.61, 95% CI= −0.64 to −0.58). The ASRM declined among all SDI quintiles from 1990 to 2019. The high-SDI countries displayed the largest decrease (APC = −0.52, 95% CI = −0.54 to −0.50). While low-SDI quintile presented the lowest decrease (APC = −0.26, 95% CI = −0.32 to −0.19) (Table 2).

### 3.3 Disease burden of gastric cancer

Gastric cancer led to a heavy health burden in China. Gastric cancer was attributable to 22,220,980 years in 2019 worldwide, with 9,824,990 years in China. From 1990 to 2019, the DALYs of gastric cancer in China increased by 19.11%, from 8,248,790 years (95% UI = 7,173,640–9,366,340 years) in 1990 to 9,824,990 years (95% UI = 8,191,720–11,632,860 years) in 2019 (Table 1).

The age-standardized DALYs declined from 905.54/100,000 (95% CI = 791.75–1,024.49/100,000) to 481.15/100,000 (95% CI = 403.20–567.36/100,000) (eAPC = −0.47, 95% CI = −0.57 to −0.35) during the study period (Table 2; Figure 2E), which showed a more significant decrease in females (eAPC = −0.58, 95% CI = −0.67 to −0.44) (Table S1).

Kuwait showed the lowest age-standardized DALYs (64.88/100,000, 95% CI = 54.13–77.72/100,000), whereas Mongolia presented the highest (1,059.24/100,000, 95% CI = 816.79–1,351.35/100,000) in 2019. The Republic of Korea had the most significant decrease in age-standardized DALY (eAPC = −0.78, 95% CI = −0.80 to −0.75) (Figure 1C; Table S2).

In terms of geographic regions, the highest age-standardized DALYs were reported in East Asia (477.93/100,000, 95% CI = 402.48–560.38/100,000) and the lowest in High-income North America (77.38/100,000, 95% CI = 74.42–79.93/100,000) in 2019 (Figure 1C; Table S2). High-income Asia Pacific experienced the greatest decline in age-standardized DALY (eAPC = −0.66, 95% CI = −0.68 to −0.64) from 1990 to 2019 (Table 2). The low-SDI countries showed the lowest DALY (1,233,250, 95% UI = 1,093,360–1,390,350) in 2019. Age-standardized DALYs declined among all five SDI quintiles, with the most significant decrease showed in High-SDI quintile (eAPC = −0.58, 95% CI = −0.59 to −0.56) during the study period (Table 2).

### 3.4 Age-specific rates of gastric cancer in China and the world in 2019

Figure 3 illustrates the age-specific incidence, mortality rates, and DALY of gastric cancer in China and the world in 2019.

Overall, the age-specific rates in China were well above the global level for each age group. In China, the incidence and mortality rates rose in parallel with age in 2019. The incidence in younger age groups (0–29 years) was less than 5/100,000, increasing sharply after 55 years. Considering the high fatality rate of gastric cancer in China, similar tendencies were observed in the age-specific mortality rates. For patients younger than 40 years, the mortality rates were less than 5/100,000, which increased sharply after 60 years.
FIGURE 1  World map of ASRs for gastric cancer in different countries and territories in 2019. (A) The ASIR of gastric cancer in 2019. (B) The ASMR of gastric cancer in 2019. (C) The age-standardized DALYs of gastric cancer in 2019.
| Characteristics | ASIR (per 100,000 persons) 1990 (95% CI) | ASMR (per 100,000 persons) 1990 (95% CI) | ASMR (per 100,000 persons) 2019 (95% CI) | ASIR (per 100,000 persons) 2019 (95% CI) | Age-Standardized DALY Rate (per 100,000 persons) 1990 (95% CI) | ASMR (per 100,000 persons) 2019 (95% CI) |
|-----------------|------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|-------------------------------------------------|------------------------------------------|
| Global          | 22.44 (21.21, 23.59)                     | 20.48 (19.25, 21.62)                     | 11.88 (10.82, 12.82)                     | -0.42 (−0.47, −0.36)                     | 490.38 (463.73, 523.70)                          | 1.87 (268.40) (245.49, 290.61)           |
| China           | 37.56 (33.08, 42.27)                     | 37.73 (33.20, 42.39)                     | 21.72 (18.31, 25.31)                     | -0.42 (−0.53, −0.30)                     | 905.54 (791.75, 1024.49)                         | 1.95 (481.15) (403.20, 567.36)           |
| Low SDI         | 11.33 (10.01, 12.51)                     | 12.09 (10.78, 13.28)                     | 8.94 (8.09, 9.89)                        | -0.26 (−0.32, −0.19)                     | 296.61 (261.86, 327.96)                         | 1.44 (211.99) (189.09, 237.06)           |
| Low-middle SDI  | 14.16 (12.98, 15.20)                     | 14.81 (13.54, 15.91)                     | 10.79 (9.86, 11.75)                      | -0.27 (−0.34, −0.19)                     | 371.10 (340.05, 399.43)                         | 1.33 (259.64) (237.33, 283.81)           |
| Middle SDI      | 24.50 (22.18, 27.08)                     | 24.85 (22.60, 27.23)                     | 14.63 (12.98, 16.34)                     | -0.41 (−0.49, −0.32)                     | 597.68 (539.40, 656.25)                         | 1.78 (323.39) (285.17, 362.95)           |
| High-middle SDI | 27.30 (25.74, 28.82)                     | 26.38 (24.76, 27.91)                     | 13.85 (12.41, 15.21)                     | -0.48 (−0.53, −0.41)                     | 636.28 (597.50, 675.77)                         | 2.19 (314.06) (280.11, 346.89)           |
| High SDI        | 21.99 (21.24, 22.41)                     | 21.64 (20.56, 22.73)                     | 13.83 (12.50, 15.15)                     | -0.52 (−0.54, −0.50)                     | 334.24 (325.39, 348.46)                         | 2.08 (145.30) (136.59, 151.74)           |
| Regions         |                                           |                                           |                                           |                                           |                                                 |                                           |
| Andean Latin America | 29.65 (26.92, 32.44)                     | 31.65 (28.85, 34.63)                     | 7.58 (7.34, 7.86)                        | -0.33 (−0.44, −0.21)                     | 716.00 (650.82, 783.72)                         | 1.34 (461.18) (373.90, 562.48)           |
| Australasia     | 10.17 (9.70, 10.57)                      | 7.58 (7.34, 7.86)                        | 4.01 (3.64, 4.32)                       | -0.47 (−0.50, −0.44)                     | 161.78 (156.20, 166.61)                         | 2.05 (84.50) (78.68, 98.98)              |
| Caribbean       | 11.30 (10.32, 12.17)                     | 11.54 (10.53, 12.21)                     | 7.97 (6.90, 9.13)                        | -0.31 (−0.40, −0.21)                     | 265.63 (239.02, 284.40)                         | 1.71 (189.55) (160.41, 220.08)           |
| Central Asia    | 28.00 (27.11, 28.78)                     | 28.11 (27.18, 29.81)                     | 16.33 (14.91, 17.86)                     | -0.42 (−0.47, −0.36)                     | 748.11 (724.79, 769.16)                         | 2.33 (400.85) (364.02, 424.66)           |
| Central Europe  | 18.06 (17.57, 18.39)                     | 18.18 (17.62, 18.53)                     | 9.38 (8.25, 10.54)                       | -0.48 (−0.54, −0.43)                     | 424.85 (415.55, 431.68)                         | 1.36 (215.06) (187.81, 242.35)           |
| Central Latin America | 19.01 (18.16, 19.56)                     | 19.69 (18.70, 20.31)                     | 11.79 (10.11, 13.75)                     | -0.40 (−0.49, −0.30)                     | 434.34 (420.65, 444.79)                         | 1.38 (268.47) (228.66, 315.56)           |
| Central Sub-Saharan Africa | 11.90 (9.86, 14.11) | 12.72 (10.78, 14.66) | 8.47 (6.95, 10.43) | -0.31 (−0.47, −0.18) | 313.58 (261.08, 371.43) | 1.96 (204.11) (163.10, 253.38) |
| East Asia       | 37.11 (32.73, 41.70)                     | 37.23 (32.83, 41.74)                     | 21.51 (18.23, 24.95)                     | -0.42 (−0.52, −0.30)                     | 895.01 (784.78, 1009.82)                        | 1.95 (477.93) (402.48, 560.38)           |

(Continues)
| Characteristics                          | ASIR (per 100,000 persons) 1900 (95% CI) | Male/Female ratio | Both | Male/Female ratio | eAPC (95% CI) | ASMR (per 100,000 persons) 1900 (95% CI) | Male/Female ratio | Both | Male/Female ratio | eAPC (95% CI) | Age-Standardized DALY Rate (per 100,000 persons) 1900 (95% CI) | Male/Female ratio | Both | Male/Female ratio | eAPC (95% CI) |
|----------------------------------------|-------------------------------------------|-------------------|------|-------------------|--------------|-------------------------------------------|-------------------|------|-------------------|--------------|--------------------------------------------------------------|-------------------|------|-------------------|--------------|
| Eastern Europe                         | 30.90                                     | 2.33              | 16.07 | 2.25              | −0.48        | 28.87                                     | 2.33              | 13.17 | 2.31              | −0.54        | 754.96                                                      | 2.39              | 230.40 | 2.30              | −0.56        |
| Eastern Sub-Saharan Africa              | 10.68                                     | 1.61              | 7.19  | 1.59              | −0.33        | 11.33                                     | 1.65              | 7.78  | 1.57              | −0.31        | 286.46                                                      | 1.51              | 184.39 | 1.54              | −0.36        |
| High-income Africa                     | 61.54                                     | 2.33              | 28.20 | 2.47              | −0.54        | 35.52                                     | 2.26              | 13.99 | 2.51              | −0.61        | 839.67                                                      | 2.11              | 264.70 | 2.34              | −0.66        |
| North Africa and Middle East           | 13.75                                     | 1.72              | 10.10 | 1.66              | −0.26        | 14.42                                     | 1.72              | 9.89  | 1.65              | −0.31        | 345.46                                                      | 1.65              | 218.12 | 1.60              | −0.37        |
| Southeast Asia                         | 10.91                                     | 1.62              | 6.72  | 1.83              | −0.38        | 11.46                                     | 1.62              | 6.68  | 1.79              | −0.42        | 280.51                                                      | 1.57              | 153.52 | 1.80              | −0.45        |
| Southern Latin America                 | 18.54                                     | 2.41              | 12.83 | 2.42              | −0.31        | 18.96                                     | 2.33              | 11.83 | 2.35              | −0.38        | 421.14                                                      | 2.48              | 256.51 | 2.41              | −0.39        |
| Tropical Latin America                 | 18.06                                     | 2.21              | 10.20 | 2.23              | −0.44        | 18.88                                     | 2.15              | 9.85  | 2.20              | −0.48        | 432.40                                                      | 2.28              | 225.67 | 2.20              | −0.48        |
| Western Europe                         | 16.14                                     | 2.06              | 9.45  | 1.95              | −0.41        | 13.74                                     | 1.99              | 6.48  | 1.89              | −0.53        | 289.10                                                      | 2.05              | 131.98 | 1.93              | −0.54        |
| Western Sub-Saharan Africa             | 10.19                                     | 1.54              | 8.65  | 1.48              | −0.15        | 11.13                                     | 1.57              | 9.54  | 1.48              | −0.14        | 248.41                                                      | 1.47              | 199.71 | 1.51              | −0.20        |

Abbreviations: ASIR, age-standardized incidence rate; ASMR, age-standardized mortality rate; ASR, age-standardized rate; CI, confidence interval; DALY, disability-adjusted life year; eAPC, estimated annual percentage change; SDI, sociodemographic index.
The age-specific DALY rate reached a high point of 1,529.10/100,000 in the 75–79 year age group (Table S3). The incidence of gastric cancer was significantly higher in males than in females among all age groups. In the subgroup analysis of gender, the age-specific incidence and mortality rates increased with age. The age-specific incidence rates reached the peak in the 80+ year age group for both genders (435.05/100,000 for males, 161.65/100,000 for females). The mortality rates were similar to the incidence rates, being higher in males. The age-standardized DALY rate was highest in the 80+ year age group (1,470.51/100,000, 95% CI = 1,278.34–1,589.33/100,000) (Table S3; Figure 3A, 3C and 3E).

The global age-specific rates were similar to those in China. Younger age groups (0–30 years) showed extremely low incidence (< 2/100,000) and mortality rates (< 1/100,000), with a sudden growth after 55 years. At the 80+ year age group, incidence and mortality rates reached the peak (154.03/100,000 and 147.35/100,000, respectively). The age-specific DALY rate was highest in the 80+ year age group (1,470.51/100,000, 95% CI = 1,278.34–1,589.33/100,000) (Table S4). The age-specific incidence rate leaped to the top of 222.10/100,000 (95% CI = 193.49–243.35/100,000) for males aged 80+ years, whereas it was 110.77/100,000 (89.33–125.23/100,000) for females aged 80+ years. The age-specific mortality rate rocketed to the highest level in the 80+ year age group among both genders (204.46/100,000 for males...
and 111.06/100,000 for females). The age-standardized DALY was highest in males aged 75–79 years (2,173.53 /100,000, 95% CI = 1,951.28–2,394.77/100,000), whereas it for females peaked in the 80+ year age group (1,069.07/100,000, 95% CI = 874.32–1,188.01/100,000) (Table S4; Figure 3B, 3D, and 3F).

### 3.5 | Age-specific trends in the incidence of gastric cancer in China

General trends of gastric cancer in China are shown in Figure 1A. However, there was a significant difference between genders and age groups. There was a worrisome rise in
the incidence of early-onset gastric cancer in China from 1990 to 2019. The 15–49 years age group presented an increasing trend during the study period (eAPC = 0.30, 95% CI = 0.22–0.63), whereas the 50–69 years and 70+ years age group presented a slight decrease trend from 1990 to 2019 (Figure 4; Table S5). In the subgroup analysis of gender, young men (15–49 years) were the only group to have increased incidence (eAPC = 0.54, 95% CI = 0.14–1.10). (Table S5).

4 | DISCUSSION

This study presented a comprehensive review of the gastric cancer burden over the last 29 years based on the latest national estimated data worldwide.

This study shows a gradual decline in ASIR, ASMR, and age-standardized DALYs in China and the world from 1990 to 2019, as well as demonstrating the variations by age and gender in China. What stands out is the V-shaped changing trends in ASRs for the period of 1990–2005, which are quite different from the global trends. We suggest that this phenomenon is associated with the development of cancer registration in China. The National Central Cancer Registry (NCCR) of China was founded in 2002, acting as the national bureau for the management of cancer registration.8 Data quality of cancer registration was not high during the period of 1990–2002. There is a potential bias in the ASRs in early period.

The ASIR of gastric cancer indicated a gradual decline during the study period. In more than half of the countries examined, gastric cancer is likely to reach rare cancer thresholds by 2035.9 The new cases of gastric cancer kept rising year-on-year, but the age-standardized incidence rate showed a downward trend in China and the world. The aging and growth of the population can explain the above phenomena.

Our results highlight a worrisome feature of a consistent increase in the incidence of early-onset gastric cancer (EOGC) among the young population in China. The result has already been observed in both high-incidence and low-incidence countries.9,10 Most early-onset patients presented a worse prognosis than late-onset gastric cancer patients.10,11 Since younger individuals have less exposure to environmental carcinogens than older ones, genetic factors may play a more relevant role in EOGC than in traditional gastric cancer. This public health issue requires monitoring in the future. Further studies are needed to investigate the cause of the increasing incidence of EOGC.

Most studies reported 1.8–2.0 times higher risk of gastric cancer in men than in women.12,13 In agreement with prior studies, our study indicated that males are 1.10–3.0-fold more likely to have gastric cancer than females. In agreement with prior studies, our study found that the incidence of gastric cancer was 2.2–2.5 times higher in males than in females in the past decade. Such differences could be attributed to lifestyle (men are more likely to be influenced by cultural reasons and take up drinking and smoking than are women14), environmental or occupational exposures, and physiological differences.15-17 Moreover, the incidence and mortality rates decreased among both sexes in China. The decreasing trends of ASIR and ASMR were more pronounced in females. The control and prevention strategies for gastric cancer in males need to be strengthened.18,19

Some risk factors, such as drinking, smoking, obesity, and unhealthy diet, increases the incidence levels of gastric cancer.20,21 Excessive consumption of salty, pickled, preserved, and fried foods (which are rich in N-nitroso compounds) in East Asian cultures, are proved to generate higher gastric cancer risk.22,23 Besides, H. pylori (Helicobacter pylori) is a contributing factor for gastric cancer. The risk of developing gastric cancer in individuals infected with H pylori is at least two times higher than those who test negative.24

During the last decade, the incidence of gastric cancer has decreased steadily owing to the reduction in risk factors in China and other countries.25 The decline benefits from better food preservation associated with refrigeration during transport and storage. The increasing consumption of fresh fruit and vegetables also plays a vital role in bringing about the
observed decline in the incidence of gastric cancer.\textsuperscript{26,27} It is now clear that the decreasing trend in gastric cancer occurrence is parallel to the decline in \textit{H. pylori} infection in both Eastern and Western populations.\textsuperscript{28-31} Powerful measures for tobacco control decreased the incidence of gastric cancer.\textsuperscript{32,33}

The downward trend in mortality might be linked to several reasons. First, treatment for \textit{H. pylori} eradication has a positive influence on the mortality of gastric cancer.\textsuperscript{28,34,35} In some prospective studies, vitamin supplementation (Vitamin C and E) or garlic was associated with the reduced mortality of gastric cancer.\textsuperscript{28,29} Besides, an advanced understanding of gastric cancer helps clinicians to treat the disease and reduce mortality effectively. The selective screening programs for high-risk populations carried out in the high-risk regions significantly reduce the mortality rates in China.\textsuperscript{36,37}

Geographical variation in the incidence and mortality rates remains high across the world. High ASIR of gastric cancer have been reported in East Asia and High-income Asia Pacific, whereas Africa and North America present low ASIR. Specific dietary patterns of the East Asian population mentioned above may account for the extremely high incidence within this region. Owing to effective screening strategies, the ASMR values in Japan and South Korea are much lower than those in other countries, despite the high ASIR.\textsuperscript{38,39} One critical point that should be emphasized here is that the completeness of the data and the cancer registries in African countries might differ significantly from the countries with high HDI; therefore, these factors might introduce a bias in the results and interpretations. So the disease burden in these regions is possible to be underestimated.

DALYs is a comprehensive indicator which reflects the disease burden.\textsuperscript{2,4} Because of the high incidence of gastric cancer and its large population, China is a major contributor to the global gastric cancer burden. From 1990 to 2019, the age-standardized DALYs decreased more pronounced in women than in men in China. These data suggest that sex is an important factor affecting gastric cancer disease burden.\textsuperscript{10}

On top of the above findings, there might be the following limitations in this paper that can be improved further. First, non-cardia and cardia gastric cancer demonstrate remarkable characteristics in the epidemiology and risk factor profiles.\textsuperscript{40} Because of the incomplete cancer diagnostic and registration practices, subsite-specific analysis of gastric epidemiology was not performed in this study. Second, we are not able to perform further analysis due to the lack of details regarding gastric cancer (such as classification, staging, and treatment received).

5 | CONCLUSION

This study outlined the Chinese and global burdens of gastric cancer from 1990 to 2019. The ASIR, ASMR, and DALYs have decrease in China and the world. However, rates and temporal trends varied substantially by gender, age, socioeconomic status, and geography. The incident and mortality rates are relatively high in China. Moreover, there was a worrisome rise in the incidence of early-onset gastric cancer in China. Specific strategies are needed to reduce the disease burden of gastric cancer.

ACKNOWLEDGMENTS

We appreciate the works by the Global Burden of Disease 2019 study collaborators. We are grateful to all the individuals who contributed to the three databases for their extensive support in finding, cataloging, analyzing data, and their efforts in data linkage and follow-up.

CONFLICT OF INTEREST

The authors declare that they have no competing interests.

ETHICAL APPROVAL STATEMENT

Not applicable.

DATA AVAILABILITY STATEMENT

Data and materials of this study are available from the corresponding author upon reasonable request.

ORCID

Yuxin He https://orcid.org/0000-0001-6474-7718

REFERENCES

1. Zhou M, Wang H, Zhu J, et al. Cause-specific mortality for 240 causes in China during 1990–2013: a systematic subnational analysis for the Global Burden of Disease Study 2013. Lancet. 2016;387(10015):251-272.
2. GBD 2017 Mortality Collaborators. Global, regional, and national age-sex-specific mortality and life expectancy, 1950-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1684-1735.
3. GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1204-1222.
4. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424.
5. Institute for health metrics and evaluation. 2017 http://ghdx.healthdata.org/gbd-results-tool.
6. Institute for health metrics and evaluation. 2017 http://ghdx.healthdata.org/record/ihme-data/gbd-2017-socio-demographic-index-sdi-1950%E2%80%932017.
7. Ahmad OB, Boschi-Pinto C, Lopez AD, Murray CJL, Lozano R, Mie Inoue. Age standardization of rates: a new WHO standard; 2001. https://www.who.int/healthinfo/paper31.pdf
8. Wei W, Zeng H, Zheng R, et al. Cancer registration in China and its role in cancer prevention and control. Lancet Oncol. 2020;21(7):e342-e349.
9. Arnold M, Park JY, Camargo MC, Lunet N, Forman D, Soerjomataram I. Is gastric cancer becoming a rare disease? A
global assessment of predicted incidence trends to 2035. Gut. 2020;69(5):823-829.
10. Bergquist JR, Leiting JL, Habermann EB, et al. Early-onset gastric cancer is a distinct disease with worrisome trends and oncogenic features. Surgery. 2019;166(4):547-555.
11. Takatsu Y, Hiki N, Nunobe S, et al. Clinicopathological features of gastric cancer in young patients. Gastric Cancer. 2016;19(2):472-478.
12. Crew KD, Neugut AI. Epidemiology of gastric cancer. World J Gastroenterol. 2006;12(3):354-362.
13. Yang L. Incidence and mortality of gastric cancer in China. World J Gastroenterol. 2006;12(1):17-20.
14. Kendler KS, Thornton LM, Pedersen NL. Tobacco consumption in Swedish twins reared apart and reared together. Arch Gen Psychiatry. 2000;57(9):886-892.
15. Camargo MC, Goto Y, Zabaleta J, Morgan DR, Correa P, Rabkin CS. Sex hormones, hormonal interventions, and gastric cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2012;21(1):20-38.
16. González CA, Agudo A. Carcinogenesis, prevention and early detection of gastric cancer: where we are and where we should go. Int J Cancer. 2012;130(4):745-753.
17. Derakhshan MH, Liptrot S, Paul J, Brown IL, Morrison D, McColl KEL. Oesophageal and gastric intestinal-type adenocarcinomas show the same male predominance due to a 17 year delayed development in females. Gut. 2009;58(1):16-23.
18. Pérez-Rodríguez M, Partida-Rodríguez O, Camorlinga-Ponce M, et al. Polymorphisms in HLA-DQ genes, together with age, sex, and Helicobacter pylori infection, as potential biomarkers for the early diagnosis of gastric cancer. Helicobacter. 2017;22(1):e12326.
19. Song M, Kang D, Yang JJ, et al. Age and sex interactions in gastric cancer incidence and mortality trends in Korea. Gastric Cancer. 2015;18(3):580-589.
20. Karimi P, Islami F, Anandasabapathy S, Freedman ND, Kamangar F. Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention. Cancer Epidemiol Biomark Prev. 2014;23(5):700-713.
21. Fang X, Wei J, He X, et al. Landscape of dietary factors associated with risk of gastric cancer: A systematic review and dose-response meta-analysis of prospective cohort studies. Eur J Cancer. 2015;51(18):2820-2832.
22. Shikata K, Kiyohara Y, Kubo M, et al. A prospective study of dietary salt intake and gastric cancer incidence in a defined Japanese population: the Hisayama study. Int J Cancer. 2006;119(1):196-201.
23. Leung WK, Wu M-S, Kakugawa Y, et al. Screening for gastric cancer in Asia: current evidence and practice. Lancet Oncol. 2008;9(3):279-287.
24. Eid R, Moss SF. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2002;346(1):65-67.
25. Peleteiro B, Padrão P, Castro C, Ferro A, Morais S, Lunet N. Worldwide burden of gastric cancer in 2012 that could have been prevented by increasing fruit and vegetable intake and predictions for 2025. Br J Nutr. 2016;115(5):851-859.
26. Kobayashi M, Tsubono Y, Sasazuki S, Sasaki S, Tsugane S. Vegetables, fruit and risk of gastric cancer in Japan: a 10-year follow-up of the JPHC Study Cohort I. Int J Cancer. 2002;102(1):39-44.
27. Wang T, Cai H, Sasazuki S, et al. Fruit and vegetable consumption, Helicobacter pylori antibodies, and gastric cancer risk: A pooled analysis of prospective studies in China, Japan, and Korea. Int J Cancer. 2017;140(3):591-599.
28. Ma J-L, Zhang L, Brown LM, et al. Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality. J Natl Cancer Inst. 2012;104(6):488-492.
29. Li W-Q, Zhang J-Y, Ma J-L, et al. Effects of treatment and vitamin and garlic supplementation on gastric cancer incidence and mortality: follow-up of a randomized intervention trial. BMJ. 2019;366:l5016.
30. Doorakkers E, Lagergren J, Engstrand L, Brusselaers N. eradication treatment and the risk of gastric adenocarcinoma in a Western population. Gut. 2018;67(12):2092-2096.
31. Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001;345(11):784-789.
32. Center CDCaP. Tobacco survey report in adult China. 2018; 2018. http://www.chinacdc.cn/yw_9324/201905/d20190530_202932.html.
33. IARC Monogr Eval Carcinog Risks Hum. Tobacco smoke and involuntary smoking. 2004;83.
34. Tsuda M, Asaka M, Kato M, et al. Effect on Helicobacter pylori eradication therapy against gastric cancer in Japan. Helicobacter. 2017;22(5):e12415.
35. Li W-Q, Ma J-L, Zhang L, et al. Effects of Helicobacter pylori treatment on gastric cancer incidence and mortality in subgroups. J Natl Cancer Inst. 2014;106(7):dju116.
36. Zhang X, Li M, Chen S, et al. Endoscopic screening in Asian Countries is associated with reduced gastric cancer mortality: a meta-analysis and systematic review. Gastroenterology. 2018;155(2):347-54.e9.
37. Leung WK, Ho HJ, Lin J-T, Wu M-S, Wu C-Y. Prior gastroscopy and mortality in patients with gastric cancer: a matched retrospective cohort study. Gastrointest Endosc. 2018;87(1):119-127.e3.
38. Hamashima C, Shabana M, Okada K, Okamoto M, Osaki Y. Mortality reduction from gastric cancer by endoscopic and radiographic screening. Cancer Sci. 2015;106(12):1744-1749.
39. Suzuki H, Gotoda T, Sasako M, Saito D. Detection of early gastric cancer: misunderstanding the role of mass screening. Gastroenterol. 2006;9(4):315-319.
40. Colquhoun A, Arnold M, Ferlay J, Goodman KJ, Forman D, Soerjomataram I. Global patterns of cardia and non-cardia gastric cancer incidence in 2012. Gut. 2015;64(12):1881-1888.